Insight

Liewei Wang: Inhibition of MTAP Increases PARP Inhibitor Susceptibility in Triple-Negative Breast Cancer

Liewei Wang/LinkedIn

Jul 21, 2025, 13:29

Liewei Wang: Inhibition of MTAP Increases PARP Inhibitor Susceptibility in Triple-Negative Breast Cancer

Liewei Wang, Professor and Chair of Pharmacology at Mayo Clinic Graduate School of Biomedical Sciences, shared a recent article she and her colleagues co-authored on LinkedIn , adding:

“Another great collaboration with Dr. Zhenkun Lou’s lab!

We recently published in JCI showing that in TNBC, inhibition of MTAP leads to lower SAM level, blunts the methylation of DNA repair proteins including MRE11, therefore, reducing HRR efficiency.

MTAP inhibition can sensitize PARP inhibitors, leading to striking tumor growth inhibition, especially in the setting of brain metastasis where methine is limited.”

Title: Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop

Authors: Xiangyu Zeng, Fei Zhao, Xinyi Tu, Yong Zhang, Wen Yang, Jing Hou, Qi Jiang, Shouhai Zhu, Zheming Wu, Yalan Hao, Lingxin Zhang, Richard M. Weinshilboum, Kaixiong Tao, Liewei Wang, Zhenkun Lou

Read the Full Article on JCI

Liewei Wang: Inhibition of MTAP Increases PARP Inhibitor Susceptibility in Triple-Negative Breast Cancer

More posts featuring Triple-Negative Breast Cancer.

brain metastasis Breast Cancer cancer Fei Zhao Jing Hou Kaixiong Tao Liewei Wang Lingxin Zhang OncoDaily Oncology PARP inhibitor Qi Jiang Richard M. Weinshilboum Shouhai Zhu triple-negative breast cancer Wen Yang Xiangyu Zeng Xinyi Tu Yalan Hao Yong Zhang Zheming Wu Zhenkun Lou

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders